Advertisement

Advertisement

MLTX Stock Latest News

Analyst Maintains Buy on MoonLake, Reiterates $45 Price Target on Strong Financing and Sonelokimab Commercial Potential

RatingsAnalyst Maintains Buy on MoonLake, Reiterates $45 Price Target on Strong Financing and Sonelokimab Commercial Potential

MoonLake Immunotherapeutics Announces $200 Million Public Offering

PremiumCompany Announcements

MoonLake Immunotherapeutics Announces $200 Million Public Offering

27d ago

MoonLake Immunotherapeutics 9M share Secondary priced at $20.00

PremiumThe Fly

MoonLake Immunotherapeutics 9M share Secondary priced at $20.00

28d ago

Buy Rating Reaffirmed on Sonelokimab’s Strong HS Data and Regulatory De-Risking; $30 Price Target Maintained

PremiumRatings

Buy Rating Reaffirmed on Sonelokimab’s Strong HS Data and Regulatory De-Risking; $30 Price Target Maintained

29d ago

Closing Bell Movers: Avis Budget jumps over 6% on Pentwater settlement

PremiumThe Fly

Closing Bell Movers: Avis Budget jumps over 6% on Pentwater settlement

29d ago

MoonLake Immunotherapeutics announces $150M offering of Class A ordinary shares

PremiumThe FlyMoonLake Immunotherapeutics announces $150M offering of Class A ordinary shares

29d ago

MoonLake Reiterated at Buy as Sonelokimab Data Underscore HS Potential; $33 Price Target Maintained

Ratings

MoonLake Reiterated at Buy as Sonelokimab Data Underscore HS Potential; $33 Price Target Maintained

29d ago

MoonLake’s SLK has ‘blockbuster potential,’ says Clear Street

The Fly

MoonLake’s SLK has ‘blockbuster potential,’ says Clear Street

29d ago

Buy Rating Reiterated on SLK’s Strong Phase 3 HS Data and BLA Path; $30 Price Target Maintained

PremiumRatings

Buy Rating Reiterated on SLK’s Strong Phase 3 HS Data and BLA Path; $30 Price Target Maintained

30d ago

Midday Fly By: Chevron signs power deal with Microsoft, CRH to acquire Arcosa

PremiumThe Fly

Midday Fly By: Chevron signs power deal with Microsoft, CRH to acquire Arcosa

30d ago

MoonLake Highlights Strong Phase 3 Sonelokimab HS Results

PremiumCompany Announcements

MoonLake Highlights Strong Phase 3 Sonelokimab HS Results

30d ago

MoonLake announces Week 52 results of Phase 3 VELA-1, VELA-2 trials

PremiumThe Fly

MoonLake announces Week 52 results of Phase 3 VELA-1, VELA-2 trials

1M ago

MoonLake shareholders back director, auditor and compensation plans

PremiumCompany AnnouncementsMoonLake shareholders back director, auditor and compensation plans

1M ago

MoonLake’s Phase 3 Sonelokimab Trial Reaches Completion in Hidradenitis Suppurativa

Company Announcements

MoonLake’s Phase 3 Sonelokimab Trial Reaches Completion in Hidradenitis Suppurativa

1M ago

Moonlake’s Phase 3 Hidradenitis Trial Hits Completion, Setting Up Key Catalyst for MLTX

Company Announcements

Moonlake’s Phase 3 Hidradenitis Trial Hits Completion, Setting Up Key Catalyst for MLTX

1M ago

MoonLake Secures Long-Term Manufacturing Capacity with Vetter Pharma

PremiumCompany Announcements

MoonLake Secures Long-Term Manufacturing Capacity with Vetter Pharma

2M ago

MoonLake Immunotherapeutics: Buy Rating Reiterated on De-Risked Path to 2026 BLA and Robust SLK Data; $30 Price Target Maintained

PremiumRatings

MoonLake Immunotherapeutics: Buy Rating Reiterated on De-Risked Path to 2026 BLA and Robust SLK Data; $30 Price Target Maintained

2M ago

Phil Nadeau Reiterates Buy on MoonLake Immunotherapeutics as Sonelokimab Advances Toward 2027 Launch with $3B+ Peak Sales Potential

PremiumRatings

Phil Nadeau Reiterates Buy on MoonLake Immunotherapeutics as Sonelokimab Advances Toward 2027 Launch with $3B+ Peak Sales Potential

2M ago

MoonLake advances sonelokimab toward BLA after positive FDA meeting

PremiumCompany Announcements

MoonLake advances sonelokimab toward BLA after positive FDA meeting

2M ago

MoonLake price target raised to $45 from $40 at H.C. Wainwright

PremiumThe FlyMoonLake price target raised to $45 from $40 at H.C. Wainwright

2M ago

MoonLake FDA meeting yields ‘best-in-class’ label, says Clear Street

The Fly

MoonLake FDA meeting yields ‘best-in-class’ label, says Clear Street

2M ago

MoonLake says aligned with FDA on submission plans for sonelokimab

The Fly

MoonLake says aligned with FDA on submission plans for sonelokimab

2M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >